98%
921
2 minutes
20
Late HIV treatment remains a global public health issue despite significant efforts. To better understand what shapes this issue, we interviewed 36 Vietnamese ART-naive patients who came to HIV treatment in 2017. Half of them had intake CD4 counts fewer than 100 cells/mm, the others had intake CD4 counts of 350 cells/mm and above. Late diagnosis was the reason of late treatment in our sample. Most late presenters were not members of the key populations at increased risk of HIV (e.g., people who inject drugs, commercial sex workers, and men who have sex with men). Individual-level factors included low risk appraisal, habit of self-medication, and fear of stigma. Network and structural-level factors included challenges to access quality health care, normalization of HIV testing in key populations and inconsistent provider-initiated HIV testing practices. Structural interventions coupled with existing key population-targeted strategies would improve the issue of late HIV diagnosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1521/aeap.2021.33.5.450 | DOI Listing |
Lancet Infect Dis
September 2025
The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis.
Methods: Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries.
Diagn Microbiol Infect Dis
August 2025
Blood Center of Zhejiang Province, Hangzhou 310006, China.
This study analyzed the correlation between false-positive HIV ELISA results (using Bio-Rad reagents) and SARS-COV-2 antibody levels in 301 unpaid apheresis platelet donors with prior infection or vaccination, enrolled from Zhejiang Blood Center between February 1 and May 31, 2023. Trends in both the HIV ELISA false-positive rate and SARS-COV-2 antibody levels were assessed. The false-positive rate rose in early 2023, peaking at 0.
View Article and Find Full Text PDFAm J Pathol
September 2025
Morrissey College of Arts and Sciences, Biology Department, Boston College, Chestnut Hill, MA, USA. Electronic address:
A challenge to eradicate HIV is the CNS reservoir and unknown mechanisms-pathways by which infected macrophages can exit. We used intracisternal (i.c.
View Article and Find Full Text PDFJ Int AIDS Soc
September 2025
ICAP at Columbia University, New York, New York, USA.
Introduction: Beginning in late January 2025, Stop-Work orders and contract cancellations have disrupted HIV programmes supported by the President's Emergency Plan for AIDS Relief (PEPFAR). We assessed the effects on HIV service delivery in four African countries.
Methods: Weekly aggregate HIV services data from a convenience sample of 165 Center for Disease Control and Prevention (CDC)-funded, ICAP-supported facilities-22 in Angola, 75 in the Democratic Republic of the Congo (DRC), 20 in South Sudan and 48 in Zambia-were analysed.
PLoS Med
September 2025
Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri, United States of America.
Background: Timely response to treatment failure is critical for improved outcomes and viral re-suppression among people living with HIV, but care gaps along the treatment failure cascade can occur due to delays by both clients (e.g., retention and adherence) and health systems (e.
View Article and Find Full Text PDF